Connection

Thomas Keane to Prostatic Neoplasms

Back to Details
This is a "connection" page, showing publications Thomas Keane has written about Prostatic Neoplasms.
Thomas Keane
Connection Strength
5.180
Prostatic Neoplasms
  1. Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease. Curr Urol Rep. 2017 Jun; 18(6):41.
    View in: PubMed
    Score: 0.367
  2. Improved performance of SPECT-CT In-111 capromab pendetide by correlation with diffusion-weighted magnetic resonance imaging for identifying metastatic pelvic lymphadenopathy in prostate cancer. World J Urol. 2013 Dec; 31(6):1327-32.
    View in: PubMed
    Score: 0.276
  3. Androgen deprivation therapy: past, present and future. BJU Int. 2012 Jun; 109 Suppl 6:1-12.
    View in: PubMed
    Score: 0.259
  4. Capromab pendetide scanning has a potential role in optimizing patient selection for salvage cryosurgical ablation of the prostate. Urology. 2010 Nov; 76(5):1162-7.
    View in: PubMed
    Score: 0.233
  5. The multi-disciplinary management of high-risk prostate cancer. Urol Oncol. 2012 Jan-Feb; 30(1):3-15.
    View in: PubMed
    Score: 0.218
  6. Evaluation of modern pathological criteria for positive margins in radical prostatectomy specimens and their use for predicting biochemical recurrence. BJU Int. 2009 Feb; 103(3):327-31.
    View in: PubMed
    Score: 0.202
  7. Perineal prostatectomy in the age of minimally invasive surgery. J Ark Med Soc. 2008 Sep; 105(3):67-8.
    View in: PubMed
    Score: 0.200
  8. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer. Urology. 2008 Jun; 71(6):1177-80.
    View in: PubMed
    Score: 0.193
  9. Pathologically confirmed port site metastasis after laparoscopic radical prostatectomy: case report and literature review. Urology. 2007 Dec; 70(6):1222.e9-11.
    View in: PubMed
    Score: 0.190
  10. Salvage options for biochemical recurrence after primary therapy for prostate cancer. Can J Urol. 2007 Dec; 14 Suppl 1:2-9.
    View in: PubMed
    Score: 0.190
  11. Salvage cryosurgical ablation of the prostate for local recurrence after radiation therapy: improved outcomes utilizing a capromab pendetide scan and biopsy algorithm. Can J Urol. 2007 Dec; 14 Suppl 1:24-7.
    View in: PubMed
    Score: 0.190
  12. Tissue disposition of 5-o-carboranyluracil--a novel agent for the boron neutron capture therapy of prostate cancer. Nucleosides Nucleotides Nucleic Acids. 2004; 23(1-2):291-306.
    View in: PubMed
    Score: 0.145
  13. PC-SPES withdrawal response. Acta Oncol. 2004; 43(8):772-3.
    View in: PubMed
    Score: 0.145
  14. Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical Data. J Urol. 2021 02; 205(2):554-560.
    View in: PubMed
    Score: 0.116
  15. Evolving understanding and categorization of prostate cancer: preventing progression to metastatic castration-resistant prostate cancer: RADAR IV. Can J Urol. 2020 10; 27(5):10352-10362.
    View in: PubMed
    Score: 0.116
  16. The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data. J Urol. 2020 Apr; 203(4):743-750.
    View in: PubMed
    Score: 0.108
  17. A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III). J Urol. 2019 04; 201(4):682-692.
    View in: PubMed
    Score: 0.104
  18. FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist. Scand J Urol. 2018 Oct - Dec; 52(5-6):349-357.
    View in: PubMed
    Score: 0.103
  19. Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. Urol Oncol. 2018 06; 36(6):310.e7-310.e13.
    View in: PubMed
    Score: 0.097
  20. The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy. Urol Oncol. 2017 05; 35(5):183-191.
    View in: PubMed
    Score: 0.090
  21. Avoiding obsolescence in advanced prostate cancer management: a guide for urologists. BJU Int. 2015 Feb; 115(2):188-97.
    View in: PubMed
    Score: 0.078
  22. Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer. Eur Urol. 2015 Feb; 67(2):334-41.
    View in: PubMed
    Score: 0.075
  23. Challenges and recommendations for early identification of metastatic disease in prostate cancer. Urology. 2014 Mar; 83(3):664-9.
    View in: PubMed
    Score: 0.072
  24. Phase I trial of weekly docetaxel, total androgen blockade, and image-guided intensity-modulated radiotherapy for localized high-risk prostate adenocarcinoma. Clin Genitourin Cancer. 2014 Apr; 12(2):80-6.
    View in: PubMed
    Score: 0.072
  25. Impact of prostate cancer on sexual relationships: a longitudinal perspective on intimate partners' experiences. J Sex Med. 2013 Dec; 10(12):3135-43.
    View in: PubMed
    Score: 0.071
  26. Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse. J Clin Invest. 2013 Oct; 123(10):4344-58.
    View in: PubMed
    Score: 0.071
  27. Burden among partner caregivers of patients diagnosed with localized prostate cancer within 1?year after diagnosis: an economic perspective. Support Care Cancer. 2013 Dec; 21(12):3461-9.
    View in: PubMed
    Score: 0.071
  28. Editorial comment. Urology. 2012 Sep; 80(3):563.
    View in: PubMed
    Score: 0.065
  29. Willingness to pay for prostate cancer treatment among patients and their family members at 1 year after diagnosis. Value Health. 2012 Jul-Aug; 15(5):716-23.
    View in: PubMed
    Score: 0.065
  30. Editorial comment. Urology. 2012 Jul; 80(1):168.
    View in: PubMed
    Score: 0.065
  31. Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J Clin Endocrinol Metab. 2012 Jul; 97(7):2315-24.
    View in: PubMed
    Score: 0.064
  32. Diagnostic performance of In-111 capromab pendetide SPECT/CT in localized and metastatic prostate cancer. Clin Nucl Med. 2011 Oct; 36(10):872-8.
    View in: PubMed
    Score: 0.062
  33. Provider and partner interactions in the treatment decision-making process for newly diagnosed localized prostate cancer. BJU Int. 2011 Sep; 108(6):851-6; discussion 856-7.
    View in: PubMed
    Score: 0.059
  34. Autophagy is increased in prostate cancer cells overexpressing acid ceramidase and enhances resistance to C6 ceramide. Prostate Cancer Prostatic Dis. 2011 Mar; 14(1):30-7.
    View in: PubMed
    Score: 0.058
  35. Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for initial consultation and second opinions. World J Urol. 2011 Feb; 29(1):3-9.
    View in: PubMed
    Score: 0.058
  36. Preliminary treatment considerations among men with newly diagnosed prostate cancer. Am J Manag Care. 2010 May 01; 16(5):e121-30.
    View in: PubMed
    Score: 0.056
  37. Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy. Expert Opin Ther Targets. 2009 Dec; 13(12):1449-58.
    View in: PubMed
    Score: 0.055
  38. Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer. Mol Ther. 2009 Mar; 17(3):430-8.
    View in: PubMed
    Score: 0.051
  39. Managing prostate cancer: the role of hormone therapy. Can J Urol. 2007 Dec; 14 Suppl 1:10-8.
    View in: PubMed
    Score: 0.047
  40. Functional analysis of the host defense peptide Human Beta Defensin-1: new insight into its potential role in cancer. Mol Immunol. 2008 Feb; 45(3):839-48.
    View in: PubMed
    Score: 0.047
  41. Adjuvant androgen deprivation therapy augments cure and long-term cancer control in men with poor prognosis, nonmetastatic prostate cancer. Prostate Cancer Prostatic Dis. 2008; 11(1):46-52.
    View in: PubMed
    Score: 0.046
  42. The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy. Cancer Biol Ther. 2007 Sep; 6(9):1455-60.
    View in: PubMed
    Score: 0.046
  43. Modulation of ceramide metabolism enhances viral protein apoptin's cytotoxicity in prostate cancer. Mol Ther. 2006 Nov; 14(5):637-46.
    View in: PubMed
    Score: 0.043
  44. Prostate cancer disparities in South Carolina: early detection, special programs, and descriptive epidemiology. J S C Med Assoc. 2006 Aug; 102(7):241-9.
    View in: PubMed
    Score: 0.043
  45. [Reevaluation of MAB therapy and progress of endocrine therapy]. Gan To Kagaku Ryoho. 2005 May; 32(5):705-28.
    View in: PubMed
    Score: 0.040
  46. The present and future for gene and viral therapy of directly accessible prostate and squamous cell cancers of the head and neck. Future Oncol. 2005 Feb; 1(1):115-23.
    View in: PubMed
    Score: 0.039
  47. Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology. 2002 Aug; 60(2):201-8.
    View in: PubMed
    Score: 0.033
  48. Evaluation of staging lymphadenectomy in prostate cancer. Urology. 1998 Oct; 52(4):663-7.
    View in: PubMed
    Score: 0.025
  49. Normal range prostate-specific antigen versus age-specific prostate-specific antigen in screening prostate adenocarcinoma. Urology. 1995 Aug; 46(2):200-4.
    View in: PubMed
    Score: 0.020
  50. Characterization of a new model of human prostatic cancer: the multicellular tumor spheroid. Int J Cancer. 1990 Aug 15; 46(2):238-44.
    View in: PubMed
    Score: 0.014
  51. Prostate-specific antigen. Superior serum marker for prostatic carcinoma. Ir J Med Sci. 1987 May; 156(5):138-41.
    View in: PubMed
    Score: 0.011
  52. Involvement of sphingolipids in apoptin-induced cell killing. Mol Ther. 2006 Nov; 14(5):627-36.
    View in: PubMed
    Score: 0.011
  53. Outcome following radiotherapy in verrucous carcinoma of the larynx. Int J Radiat Oncol Biol Phys. 1995 Jun 15; 32(3):611-7.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.